Prostate Cancer News

When men have advanced prostate cancer, obesity might offer something of a survival advantage, a preliminary study suggests.

Researchers analyzed medical records of men treated for prostate cancer by the U.S. Veterans' Health Administration -- most were over 60 with no other serious health issues.

Researchers have identified a potential new treatment for metastatic castration-resistant prostate cancer, which has no cure.

Negative biopsies among early-stage prostate cancer patients who've chosen active surveillance are associated with a low risk of disease progression, but they aren't a sign that their cancer has completely vanished, a new study indicates.

Roker, 66, told viewers he will leave the show for a while to have surgery.

Education, income and insurance may be fueling racial disparities in U.S. prostate cancer deaths -- disparities that have black patients dying at higher rates than whites.

For men with advanced prostate cancer, a new hormone therapy pill works better than standard injections -- and carries a much lower risk of heart attack or stroke.

New research suggests that recommendations against routine prostate cancer testing may have come at a steep price -- more men getting diagnosed with advanced prostate cancers.

Having a BMI (body mass index -- an estimate of body fat based on height and weight) above the range that's considered healthy (21-25) during middle to late adulthood was associated with the highest risk for advanced prostate cancer.

After two years of follow-up, the group on the vegetable-rich diet saw no extra protection against prostate cancer compared to the control group, according to findings published Jan. 14 in the Journal of the American Medical Association.

According to new Swedish research that suggests that men who become fathers through assisted reproduction treatments may be more likely to develop prostate cancer in midlife.

Running contrary to current guidelines, new research suggests that use of hormone-suppressing treatment over the long term may not help some men battling recurrent prostate cancer, and may even cause harm.

The American Cancer Society estimates there will be nearly 175,000 new prostate cancer cases in the United States this year and over 31,000 deaths. One in nine men will be diagnosed with prostate cancer in their lifetime.

In total, 13% of men who had received the therapy went on to develop Alzheimer's disease over eight years of follow-up, compared to 9%  who hadn't gotten the treatment, the study found.

Researchers from the United Kingdom report that they've created a urine test that can predict the aggressiveness of a prostate cancer far sooner than standard methods.

Exposure to dust at the New York City site after the terrorist attacks triggered chronic inflammation in the responders' prostates, which may have contributed to their cancer, researchers said.

The researchers found that very few patients who chose active surveillance actually received the recommended monitoring, one of the study authors said.

Two drugs that interfere with cancer's ability to use testosterone for fuel, apalutamide (Erleada) and enzalutamide (Xtandi), are already approved for use against more advanced prostate tumors that don't respond to regular therapy.

Changes in chromosomes within prostate cancer cells may help predict how aggressive a tumor is, a new study has found.

The effect was found only with atenolol (Tenormin). Two other beta blockers -- metoprolol (Lopressor/Toprol XL) and carvedilol (Coreg) -- did not appear to provide any protection against prostate cancer.

High-dose radiation could be more convenient for low-risk patients, and less time-consuming and costly for the medical system.

Of the 44 countries studied, prostate cancer rates rose in four and fell in seven. The United States had the biggest decrease. Rates remained stable in the 33 other countries.

Any potential benefit from low-dose aspirin needs to be weighed against the risk of gastrointestinal bleeding linked with its use, researchers said.

Over just five years, researchers found, the number of men who opted for monitoring tripled -- from 14 percent of patients in 2010, to 42 percent in 2015.

The newly released long-term data show that the reduction of prostate cancer risk has continued and that fewer than 100 men in the study of nearly 19,000 died from prostate cancer in more than two decades of follow-up.